Your session is about to expire
← Back to Search
risedronate for Lung Cancer
Study Summary
This trial will compare the rate of bone loss in patients with peripheral lung tumors who are treated with SBRT with or without a single dose of 150 mg risedronate given prior to treatment.
- Lung Cancer
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2013 Phase 4 trial • 109 Patients • NCT00485953Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there any participants currently being enrolled for this research?
"This trial is no longer in search of patients. The research was first published on July 12th 2019 and last edited on September 13th 2022, so it has since been concluded. However, there are currently 1493 clinical trials for neoplasms, lung diseases, and risedronate that are still recruiting participants."
Are there any preceding reports regarding the efficacy of risedronate?
"Presently, 3 clinical trials for risedronate are active with 1 in Phase 3. While Winston-Salem is a primary site, there exist 4 additional locations offering the medication trial."
Has the FDA given its endorsement to risedronate?
"Considering the Phase 2 status of this trial and existing safety data, our team gave risedronate a score of two. However, there is no evidence yet to confirm its efficacy."
What is the upper limit for enrollment in this clinical experiment?
"This study has concluded its patient recruitment. It was initially posted on July 12th 2019 and the last edit occured on September 13th 2022. There are several other trials looking for neoplasm, lung, or risedronate patients with 1493 and 3 active recruitments respectively."
To what medical conditions is risedronate typically prescribed?
"Risedronate is a common remedy for osteoporosis, however it can also be employed to address malignant neoplasms, postmenopausal issues, and bone-related ailments."
Share this study with friends
Copy Link
Messenger